IntroductionPatients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC) have historically had limited treatment options. Surgery, the primary course of treatment for most BCCs, and radiotherapy are often not viable options in advanced BCC. In recent years, hedgehog (Hh) pathway inhibitors (HPIs) were developed to block aberrant Hh signalling that is found in most sporadic BCCs; HPIs have demonstrated efficacy in patients with laBCC and those with mBCC.Sonidegib (LDE225), which inhibits Hh signalling by targeting the Hh pathway component smoothened, was approved (200 mg once daily) in the United States and Europe for the treatment of laBCC, in Australia for the treatment of laBCC and mBCC and in Switzerland for the treatment of advanced BCC that cannot be treated with curative surgery or radiotherapy. These approvals were based on results from the pivotal phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) study (NCT01327053), in which the primary analysis was performed using data based on 6 months of follow‐up. Here, we report long‐term efficacy and safety results from BOLT, with up to 30 months of follow‐up after the last patient was randomized.Materials and methodsBOLT study design and patientsBOLT is a randomized, double‐blind, phase 2 study conducted in 58
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera